New Releases from NCBI BookshelfCapivasertib (Truqap): Indication: Capivasertib is indicated in combination with fulvestrant for the treatment of adult females with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy: CADTH Reimbursement Recommendation [Internet].​Capivasertib (Truqap): Indication: Capivasertib is indicated in combination with fulvestrant for the treatment of adult females with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy: CADTH Reimbursement Recommendation [Internet].